Recruiting

Testing a new injectable treatment for heart and lung problems in people with obesity

Plain-English translation of NCT07123779 on ClinicalTrials.gov ↗ · Source last updated October 2026 · Translation generated August 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This study is testing a medication called , given as an injection under the skin, to see if it can help people who are obese and have two related heart and lung problems: high pressure in the blood vessels of the lungs and a type of heart failure where the heart doesn't pump weakly but doesn't relax properly. The trial will measure whether the medication is safe and whether it actually helps patients feel better and exercise more.

People with obesity often develop high lung pressure combined with this specific type of heart failure, and current treatments don't work well enough for everyone. This medication is being tested because it may target the root causes of both conditions and improve outcomes for patients who haven't responded well to other treatments.

Do you qualify?

You likely qualify if…

you are 18 years old or older
you have been diagnosed with heart failure with preserved ejection fraction (a specific type where your heart doesn't squeeze weakly) with a heart function score of 45% or higher
you have high blood pressure in your lungs, confirmed by heart testing
you have a body mass index between 30 and 50, and weigh no more than 140 kilograms (about 310 pounds)
you experience moderate heart failure symptoms, such as shortness of breath with activity
you can walk at least 100 meters (about 330 feet) in six minutes

You likely don't qualify if…

you have been hospitalized or had major surgery in the past four weeks
you have had a heart attack, cardiac procedure, or heart surgery in the past three months
you have serious irregular heartbeats or were treated for them in the past three months
you have significant lung disease, such as severe emphysema, or moderate to severe sleep apnea
you are being considered for heart transplant or have had one in the past

What participation looks like

If you enroll, you will receive either or a placebo (inactive injection) under the skin at multiple clinic visits over the study period. You'll have blood tests, heart imaging, walking tests, and questionnaires about your symptoms. Some participants will have a special remote heart pressure monitor implanted as part of the study to track how your lungs and heart respond to the treatment. The study involves both a Phase 1 portion (which focuses on safety) and a Phase 2 portion (which focuses on whether the medication works).

AI-generated summary from trial data · Aug 21, 2026 · Not medical advice

Trial locations(3 sites)

United States

Investigational Site-105, Kansas City, Missouri

Investigational Site-101, Greenville, South Carolina

Investigational Site-103, Dallas, Texas